These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23828933)

  • 1. Immunology. Making macrophages eat cancer.
    Kershaw MH; Smyth MJ
    Science; 2013 Jul; 341(6141):41-2. PubMed ID: 23828933
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour immunology: cracking the combination.
    Bordon Y
    Nat Rev Immunol; 2013 Jul; 13(7):469. PubMed ID: 23743478
    [No Abstract]   [Full Text] [Related]  

  • 3. Anticancer drugs: Cracking the combination.
    Bordon Y
    Nat Rev Drug Discov; 2013 Jul; 12(7):505. PubMed ID: 23812266
    [No Abstract]   [Full Text] [Related]  

  • 4. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
    Weiskopf K; Ring AM; Ho CC; Volkmer JP; Levin AM; Volkmer AK; Ozkan E; Fernhoff NB; van de Rijn M; Weissman IL; Garcia KC
    Science; 2013 Jul; 341(6141):88-91. PubMed ID: 23722425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the mechanism of CD47 targeting in cancer.
    Zhao XW; Matlung HL; Kuijpers TW; van den Berg TK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2843; author reply E2844-5. PubMed ID: 22923695
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.
    Soto-Pantoja DR; Miller TW; Frazier WA; Roberts DD
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2842; author reply E2844-5. PubMed ID: 22923696
    [No Abstract]   [Full Text] [Related]  

  • 9. Marker-of-self becomes marker-of-senescence.
    Sosale N; Discher DE
    Blood; 2012 Jun; 119(23):5343-4. PubMed ID: 22679336
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspectives on anti-CD47 antibody treatment for experimental cancer.
    Unanue ER
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):10886-7. PubMed ID: 23784781
    [No Abstract]   [Full Text] [Related]  

  • 11. CD47 checkpoint data supercharge Stanford spinout IPO.
    Dolgin E
    Nat Biotechnol; 2018 Aug; 36(8):671-672. PubMed ID: 30080839
    [No Abstract]   [Full Text] [Related]  

  • 12. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 13. [Biological immunomodulators in the treatment of cancer].
    Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
    Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
    [No Abstract]   [Full Text] [Related]  

  • 14. The therapeutic use of antibodies for malignancy.
    Johnson PW
    Transfus Clin Biol; 2001 Jun; 8(3):255-9. PubMed ID: 11499972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 16. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Affinity SIRPα Variants Potentiate Antibody Therapy Efficacy.
    Cancer Discov; 2013 Jul; 3(7):716. PubMed ID: 23847342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
    Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
    Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target.
    Takimoto CH; Chao MP; Gibbs C; McCamish MA; Liu J; Chen JY; Majeti R; Weissman IL
    Ann Oncol; 2019 Mar; 30(3):486-489. PubMed ID: 30689700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.